GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations To the Editor:
About 20 recurrently mutated genes are known to be involved in the molecular pathogenesis of acute myeloid leukemia (AML) [1] . Among them, Nucleophosmin (NPM1) and FLT3-ITD mutations frequently occur together in adults with AML [2] , suggesting cooperative leukemogenesis. To date, the molecular consequences of these cooperative genetic alterations in AML are still elusive.
To address this issue, we crossed Npm1 and Flt3-ITD mutant mice demonstrating the onset of lethal AML ( Fig. 1a and Figure S1 ). Interestingly, the cumulative mutant allele burden influenced the leukemic phenotype, penetrance and latency. NPM1/Flt3-ITD double heterozygous mice (Npm1 ) showed the higher white blood cell (WBC) counts, a significant spleen enlargement (Fig. 1a ii-iii) and developed AML rapidly regardless of NPM1 mutation dosage, suggesting that in the context of a high FLT3 kinase activity even small NPM1 mutant levels are leukemogenic. This supports a direct oncogenic effect of the NPM1 mutant, beside the haploinsufficient tumor suppressor effects of the concomitant loss of one NPM1 allele [3, 4] . Additionally, our data are in line with the clinical observation that normal karyotype AML with high FLT3-ITD levels have a poor outcome [5] .
The analysis of the Npm1 (Fig. 1b i-ii) .
Flow cytometry analysis of bone marrow (BM) populations showed that leukocytosis was associated to reduced long-term hematopoietic stem cells (HSCs), significant expansion of multipotent progenitor (MPP) cells and a 6.1-fold increase of granulocyte/monocyte progenitors (GMPs) (Fig. 1b iii-iv) . Npm1
+/TCTG
;Flt3 +/ITD mice had decreased number of immature and recirculating B-cell BM populations ( Figure S2 ). Erythrocyte changes reflected a significant reduction in the corresponding BM populations at different differentiation stages including myelo-erythroid progenitors (MEP), premegakaryocyte-erythrocyte progenitors (PreMegE), precolony forming unit-erythroid (pre-CFU-E), CFU-E and proerythroblasts (proEry) that resulted almost absent (Fig. 1b v-vi and Figure S3 ). In physiological hematopoiesis, FLT3 upregulation is important in sustaining MPP and GMP but not MEP potential [6] . In Npm1 ;Flt3 +/ITD BM samples displayed a significant deregulation of factors involved in megakaryocyte development and platelet production. Interestingly, several genes associated with this pathway were linked to a GATA transcriptional signature, including GATA1, Zpfm1, Rac1 and Ehd2. The latter showed a significant downregulation, with GATA1 displaying the lower levels ( Figure S4 ). A similar expression signature was present in lineage-depleted BM cells used to exclude biases related to the different cellular composition of leukemic versus wild-type mice ( Figure S5 ). In this context, we found a higher number of deregulated GATA gene family members including GATA1, GATA2 and GATA3.
Results of GEPs and the presence of alterations in erythropoiesis before AML development prompted us to focus 
;Flt3
+/ITD mice were accompanied by a dramatic reduction of GATA1 messenger RNA (mRNA) and complete loss and substantial downregulation of protein expression in both total or lineagedepleted BM (Fig. 1c ii-iii) . The extent of GATA1
Ex2 and Figure S7A ) rescued most of the preleukemic phenotype which included a significant reduction of WBC and neutrophils in peripheral blood (PB) and a decrease in percentage of MPP and GMP (Fig. 1d ii,iv and Figure S7B ). Interestingly, GATA1 re-expression also led to a rescue of macrocytosis with a significant reduction of the MCV values from 58.7 to 50.2 fL (Fig. 1d iii) . Moreover, spleens from GATA1-rescued mice showed a decrease in size and a reduction of myeloid-infiltrating cells compared to controls ( Figure S7C ). Collectively, these findings provide evidence that deregulation of GATA1 plays a key role in the hemopoietic changes preceding AML in Npm1
mice. This is consistent with the concept that in blood cell precursors, GATA1 is necessary for erythroid lineage differentiation and antagonizes the activity of myeloid transcription factors [7] . Our findings are consistent with the observation that GATA1 heterozygous knock-out female mice frequently develop a myeloproliferative disorder with a splenic accumulation of proerythroblasts and megakaryocytes, anemia and thrombocytopenia [7] . Moreover, recurrent GATA1 mutations abrogating the expression of the full-length GATA1 have been found in myeloid proliferations related to Down syndrome, including transient abnormal myelopoiesis and megakaryoblastic AMLs [8] . Interestingly, FLT3-ITD mutations were more frequent in AML patients who lacked GATA1 expression [9] and even IDH-mutated AML patients displayed a distinct methylation signature, including the aberrant hypermethylation of GATA1/2 gene promoter [10] .
Proteasome inhibition of Npm1 +/TCTG ;Flt3 +/ITD BM cells in vitro did not rescue GATA1 protein expression ( Figure S8A ), suggesting that NPM1 and Flt3-ITD mutations regulate GATA1 transcription. Thus, we explored changes in the methylation status of the GATA1 promoter region (from −811 to −627 bp) and observed dense DNA methylation in Npm1 +/TCTG ;Flt3 +/ITD samples (Fig. 2a i-ii) .
To support GATA1 epigenetic silencing as a mechanism favoring AML, we treated Npm1
;Flt3 +/ITD mice with the DNA methyltransferase inhibitor 5-aza-deoxycytidine (5-Aza-dC). This resulted in the reactivation of GATA1 expression in BM (Fig. 2a iii and Figure S8B ), normalization of leukocytosis and prevention of a drop in platelet counts ( Fig. 2a iv-v) . Although 5-Aza-dC treatment had no impact on MCV, both MEP and Ter119 cells were significantly expanded in treated animals (Fig. 2a vi) . Flow cytometry of spleen demonstrated a significant reduction of both mature and immature myeloid cells in 5-Aza-dCtreated mice (Fig. 2a vii) . Our findings are reminiscent of the differential methylation of GATA target genes previously reported in AML mouse models combining FLT3-ITD to either IDH mutants [11] or TET2 loss [12] . The higher 5'-GATA1 methylation in Npm1 +/TCTG ;Flt3
mice points to a gene dose effect for GATA1 during leukemogenesis being finely tuned by CpG methylation. This suggests that NPM1 alterations may contribute to epigenetic modifications, especially in the presence of other mutations, such as Flt3-ITD. This view is consistent with NPM1 being an histone chaperone that interacts with linker histone H1, plays a role in sperm chromatin remodeling, enhances acetylation-dependent chromatin transcription and controls ribosomal DNA gene transcription [13] .
To assess the relevance of mouse findings to human AML, we correlated GATA1 mRNA expression with the NPM1 and FLT3-ITD mutational status in the BM of 47 AML, demonstrating that patients harboring both mutations displayed the lowest expression of GATA1 (Fig. 2b i) . The median GATA1 level of 0.44 was arbitrarily used as cut-off to distinguish high and low expressing patients. AMLs with low GATA1 were more frequent among NPM1-mutated/ FLT3-ITD AMLs than unmutated, single NPM1 or FLT3-ITD-mutated patients (72 vs 31, 46 and 57% respectively; pie charts in Fig. 2b i) . These findings were further validated in an independent database of 266 AML of the Munich Leukemia Laboratory (www.ncbi.nlm.nih.gov/geo, accession number (GSE16015) ( Figure S9 ). Additionally, we explored the methylation status of the GATA1 promoter region in 24 patients, revealing a significant DNA methylation in NPM1-mutated/FLT3-ITD samples with an (ii) GATA1 promoter methylation frequency in AML patients with NPM1/FLT3-ITD mutation (n = 8) as compared to unmutated (n = 4), NPM1 (n = 8) and FLT3-ITD (n = 4) single mutant. (iii) GATA1 mRNA levels in the BM of human AML patients (n = 3) before and after in vivo Aza treatment. N.S. not significant; *p < 0.05, **p < 0.01; ***p < 0.001; unpaired t-test with Welch's correction average of 78.1% ± 1.3 methylated CpG sites compared to 68.8% ± 2.6 in NPM1-mutated only, 69% ± 0.7 in FLT3-ITD-mutated only and 64% ± 3.1 in wild-type (Fig. 2b ii) . Finally, the analysis of GATA1 expression levels was performed in BM samples from 3 NPM1-mutated/FLT3-ITD patients treated with 5-Aza-dC, revealing a significant up-regulation of GATA1 mRNA after the first cycle (Fig. 2b iii) . These data corroborate a potential role for DNA methylation of GATA1 promoter in the development of NPM1-mutated/FLT3-ITD AML. Our findings are also of potential clinical relevance, as GATA1 transcriptional response to 5-Aza-dC in mice results in significant improvement of the myeloid phenotype. Similarly, we observed GATA1 mRNA up-regulation in two NPM1-mutated/FLT3-ITD AML patients upon 5-Aza-dC treatment.
In conclusion, we identified deregulation of GATA1 as a new feature of Npm1/Flt3-ITD AML in mice and humans. This is an early event altering the HSC fate and sensitizing cells to further malignant transformation. Our model may also be valuable for further assessment of FLT3 inhibitors [14] and other drugs that have been shown to be active against NPM1-mutated AML [15] .
